tbuckley/cabot-search huggingface dataset:
Abstract 191: Deletion or Knockdown of Myotonic Dystrophy Protein Kinase Does Not Affect Cardiac Conduction or Ejection Fraction in Mice
Authors: Samuel Carrell, David Auerbach, Sanjay Pandey, Frank Bennett, Robert Dirksen, Charles Thornton
Journal: Circulation Research (2015)

Myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy in adults, causes dominantly-inherited muscle weakness, defects of cardiac conduction, variable LV dysfunction, and risk of sudden death. The genetic basis is an expanded CTG repeat in the 3’ untranslated region of DMPK. DM1 patients are functionally hemizygous for DMPK protein, due to nuclear retention of mRNA having expanded repeats. The cardiac aspects are attributed to DMPK loss, toxicity of RNA with expanded repeats, or both. Dmpk heterozygous (+/-) and homozygous knockout (-/-) mice were reported to show AV conduction abnormalities resembling DM1 (Berul et al, JCI, 1999). In an effort to reduce RNA toxicity, antisense oligonucleotides (ASOs) targeting DMPK mRNA have recently entered clinical trials. DM1 phenotypes in skeletal muscle were corrected by ASO knockdown of toxic RNA in mice (Wheeler et al, Nature, 2012). While ASOs may have similar potential to mitigate RNA toxicity in the heart, there is risk of aggravated DMPK deficiency. To reexamine the role of DMPK in the conduction system we studied mice with Dmpk gene deletion or ASO knockdown. We obtained ECGs and echocardiograms on Dmpk -/- and +/- mice, compared to WT littermates. The +/- mice were treated with Dmpk-targeting ASOs or saline. Subcutaneous injection of 50 mg/kg/wk ASO was started at age 2 months, then shifted to biweekly injections after 6 weeks. Dmpk expression in hearts of +/- mice was ~50% of WT, and was further reduced by ASOs (84 ± 3% decrease of mRNA, 93 ± 2% decrease of protein, relative to WT). Surface ECGs and echocardiography at 6 and 10 months showed no differences of heart rate, cardiac conduction, or ejection fraction in WT, saline-treated +/-, ASO-treated +/-, or -/- mice. Conscious, unrestrained ECGs obtained at 11-12 months by radiotelemetry showed no differences among WT, saline-treated +/-, ASO-treated +/-, or -/- mice. We conclude that ASOs can induce posttranscriptional silencing of Dmpk in murine hearts. Constitutive absence of DMPK did not impact cardiac conduction or contractility, and the same was true for ASO knockdown to levels &lt;15% of WT. Our data support the idea that cardiac dysfunction in DM1 results mainly from RNA toxicity, which potentially could be prevented or alleviated by ASOs.
Techniques in Bedside Hemodynamic Monitoring.
Journal: Annals of Internal Medicine (1977)

techniques in bedside hemodynamic monitoring is available in our book collection an online access to it is set as public so you can download it instantly. Our book servers spans in multiple countries, allowing you to get the most less latency time to download any of our books like this one. Merely said, the techniques in bedside hemodynamic monitoring is universally compatible with any devices to read.
Hypopyon and Klebsiella Sepsis
Authors: Osama M Mustafa, Patricio M Aduriz-Lorenzo
Journal: New England Journal of Medicine (2016)

A 49-year-old man with diabetes was found to have blurred vision after admission to the hospital for investigation of elevated creatinine, liver enzymes, and bilirubin. He had been receiving treatment for bacteremia caused by Klebsiella pneumoniae associated with renal cortical abscesses.
M29 Trying to cause less pain for our patients! Using local anaesthesia for arterial blood gas sampling: Abstract M29 Table 1
Authors: N Maningo, S Chaudhry, A Parwaiz, B Suwal, RA Evans, RH Green, I Valero-Sanchez
Journal: Thorax (2015)

<h3>Background</h3> Direct radial artery puncture (DRAP) is considered the gold standard procedure for arterial blood gas (ABG) sampling, but it is associated with significant pain. The current ‘BTS guidelines for oxygen use in adult patients’ recommend using local anaesthesia (LA) for all ABG sampling except in emergency situations. LA can be administered subcutaneously or topically. <h3>Aims</h3> To assess the attitudes towards LA for ABG sampling in a population of medical junior doctors (JD). To assess the effectiveness of topical lidocaine cream for ABG sampling by DRAP for respiratory inpatients. <h3>Methods</h3> Firstly, we surveyed a population of JD working in our Hospital using an electronic survey platform (Surveymonkey®). Secondly, a group of inpatients requiring ABG sampling were surveyed over two months whereby half received topical LA and half did not. The LA used was Denela® 5% cream (Lidocaine 2.5% + Prilocaine 2.5%) applied 10 to 15 min prior to DRAP. Pain associated with DRAP was assessed using a combination of the Wong-Baker FACES pain rating visual scale<sup>1</sup> and a visual analogue pain scale, both scoring the pain from 1 (“no pain”) to 6 (“worst pain”). <h3>Results</h3> 68 JD were contacted and 26 responses were received (shown in Table 1). 56 DRAP were performed for ABG sampling, 50% received topical LA. The median (inter-quartile range) pain score was reduced with LA prior to DRAP (2.0 [1.8] “moderate pain”) compared to performing DRAP without LA (3.0 [4.0] “severe pain”), p &lt; 0.008. The doctors reported insignificant interruption to their ward duties by using topical LA. <h3>Conclusions</h3> Currently, LA is not used routinely as part of the ABG sampling by DRAP in our centre. Pain was significantly reduced with the use of LA when performing DRAP. These data will help inform quality improvement projects designed to implement the usage of LA for ABG sampling using DRAP as per BTS recommendations. <h3>Reference</h3> 1 Baker C. <i>Orthopaedic Nursing</i> 1987;<b>6</b>(1):11–2
Use of Plant-Based Therapies and Menopausal Symptoms
Authors: Oscar H. Franco, Rajiv Chowdhury, Jenna Troup, Trudy Voortman, Setor Kunutsor, Maryam Kavousi, Clare Oliver-Williams, Taulant Muka
Journal: JAMA (2016)

<h3>Importance</h3> Between 40% and 50% of women in Western countries use complementary therapies to manage menopausal symptoms. <h3>Objective</h3> To determine the association of plant-based therapies with menopausal symptoms, including hot flashes, night sweats, and vaginal dryness. <h3>Data Sources</h3> The electronic databases Ovid MEDLINE, EMBASE, and Cochrane Central were systematically searched to identify eligible studies published before March 27, 2016. Reference lists of the included studies were searched for further identification of relevant studies. <h3>Study Selection</h3> Randomized clinical trials that assessed plant-based therapies and the presence of hot flashes, night sweats, and vaginal dryness. <h3>Data Extraction</h3> Data were extracted by 2 independent reviewers using a predesigned data collection form. <h3>Main Outcomes and Measures</h3> Hot flashes, night sweats, and vaginal dryness. <h3>Results</h3> In total, 62 studies were identified, including 6653 individual women. Use of phytoestrogens was associated with a decrease in the number of daily hot flashes (pooled mean difference of changes, −1.31 [95% CI, −2.02 to −0.61]) and vaginal dryness score (pooled mean difference of changes, −0.31 [95% CI, −0.52 to −0.10]) between the treatment groups but not in the number of night sweats (pooled mean difference of changes, −2.14 [95% CI, −5.57 to 1.29]). Individual phytoestrogen interventions such as dietary and supplemental soy isoflavones were associated with improvement in daily hot flashes (pooled mean difference of changes, −0.79 [−1.35 to −0.23]) and vaginal dryness score (pooled mean difference of changes, −0.26 [−0.48 to −0.04]). Several herbal remedies, but not Chinese medicinal herbs, were associated with an overall decrease in the frequency of vasomotor symptoms. There was substantial heterogeneity in quality across the available studies, and 46 (74%) of the included randomized clinical trials demonstrated a high risk of bias within 3 or more areas of study quality. <h3>Conclusions and Relevance</h3> This meta-analysis of clinical trials suggests that composite and specific phytoestrogen supplementations were associated with modest reductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sweats. However, because of general suboptimal quality and the heterogeneous nature of the current evidence, further rigorous studies are needed to determine the association of plant-based and natural therapies with menopausal health.
Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease
Authors: Peter J. Barnes
Journal: Pharmacological Reviews (2016)

Multiple kinases play a critical role in orchestrating the chronic inflammation and structural changes in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD). Kinases activate signaling pathways that lead to contraction of airway smooth muscle and release of inflammatory mediators (such as cytokines, chemokines, growth factors) as well as cell migration, activation, and proliferation. For this reason there has been great interest in the development of kinase inhibitors as anti-inflammatory therapies, particular where corticosteroids are less effective, as in severe asthma and COPD. However, it has proven difficult to develop selective kinase inhibitors that are both effective and safe after oral administration and this has led to a search for inhaled kinase inhibitors, which would reduce systemic exposure. Although many kinases have been implicated in inflammation and remodeling of airway disease, very few classes of drug have reached the stage of clinical studies in these diseases. The most promising drugs are p38 MAP kinases, isoenzyme-selective PI3-kinases, Janus-activated kinases, and Syk-kinases, and inhaled formulations of these drugs are now in development. There has also been interest in developing inhibitors that block more than one kinase, because these drugs may be more effective and with less risk of losing efficacy with time. No kinase inhibitors are yet on the market for the treatment of airway diseases, but as kinase inhibitors are improved from other therapeutic areas there is hope that these drugs may eventually prove useful in treating refractory asthma and COPD.
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia
Authors: L M Saleh, W Wang, S E M Herman, N S Saba, V Anastas, E Barber, M Corrigan-Cummins, M Farooqui, C Sun, S M Sarasua, Z Zhao, N K Abousamra, O Elbaz, H A Abdelghaffar, A Wiestner, K R Calvo
Journal: Leukemia (2016)
Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434
Authors: Stuart S. Winter, Meenakshi Devidas, Si Chen, Barbara Asselin, William L. Carroll, Brent L Wood, Natia Esiashvili, Briegel J Nikki, Robert J. Hayashi, Mignon L. Loh, Andrew J. Carroll, Nyla A. Heerema, Elizabeth Raetz, Naomi J. Winick, Stephen P. Hunger, Kimberly P. Dunsmore
Journal: Blood (2015)
Conceptual and methodological issues in the comparison of inpatient psychiatric facilities
Authors: N A Goodban, P B Lieberman, M A Levine, B M Astrachan, V Cocilovo
Journal: American Journal of Psychiatry (1987)

The authors compared the length of stay of acute admission patients at a mental health center and a nearby state hospital. The two facilities had significantly different length of stay distributions; the mean was not an adequate index to describe these patterns. Despite careful matching, patients at the state hospital were more disabled. Different patient characteristics were associated with length of stay at the two facilities, and these were also characteristics on which the patient populations differed at admission. The authors conclude that comparisons of hospitals, for example, on mean or median length of stay can be misleading unless the different functions, policies, and constraints of the facilities are taken into account.
Abstract 300: The Actin Cytoskeleton Confers Specificity of Cx43 Delivery to Intercalated Discs
Authors: Shan-Shan Zhang, SoonGweon Hong, Luke P Lee, Robin M Shaw
Journal: Circulation Research (2014)

Connexin 43 (Cx43) gap junctions (GJs) electrically couple ventricular cardiomyocytes at the intercalated disc (ID), orchestrating organized organ level contraction with each heartbeat. Disease-related disruption of the Cx43 cytoskeletal trafficking machinery is associated with mislocalization of the Cx43 gap junction protein away from the ID and lethal arrhythmias. We recently found that the majority of intracellular Cx43 cargo is associated with actin, not microtubules, and is either paused or moving slowly. It is not understood why actin is involved in Cx43 trafficking. Using micropatterned HeLa cell pairs and whole-cell automated single particle tracking algorithms, we detected that distinct actin polarity exists in the cell, including highly oriented long fibers associated with fast-moving Cx43 cargo aligned toward actively forming GJ plaques. F-actin disruption with latrunculin A (LatA) leads to a loss of Cx43 cargo directionality toward the cell-cell border, as well as a marked decrease in overall microtubule length. We also found a LatA-dependent biochemical interaction between β-actin and the microtubule plus-end-binding protein EB1, which leads growing microtubules and is a necessary component of the Cx43 forward trafficking machinery. In live cell pairs, F-actin disruption resulted in a decrease in overall EB1 activity and in the number of fully extended microtubules that reach the cell-cell border. Together, these results indicate that actin contributes to the specificity of Cx43 delivery by directing EB1-based microtubule growth toward the cell-cell junction (Please refer to attached diagram).
Lymphatic Path of the Inguinal Lymph Node Metastases in Anorectal Cancer
Authors: Georgios Gemenetzis, Vassilios Smyrniotis, Pantelis Vassiliu
Journal: Clinical Nuclear Medicine (2016)

Gemenetzis, Georgios MD; Smyrniotis, Vassilios MD, PhD; Vassiliu, Pantelis MD, PhD, FACS Author Information
Case 30-1971
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Robert W. Carey, Austin L. Vickery, Martin C. Mihm
Journal: New England Journal of Medicine (1971)

Presentation of Case First admission. A 60-year-old woman was admitted to the hospital because of carcinoma of the bladder.Sixteen years previously x-ray studies at another hospital disclosed a duodenal ulcer. Eleven years and again six years before admission she passed renal stones. Ten months before entry, because of the finding of hypercalcemia, an exploration of the neck was performed, with the removal of a parathyroid adenoma. Seven months before admission dysuria, urinary frequency and hematuria occurred, and cystoscopic examination revealed a large papillary tumor of the urinary bladder. Fulguration and a partial cystectomy were performed. During the next five . . .
Children with suspected diabetes should be seen by a specialist immediately, says NICE
Authors: Jacqui Wise
Journal: BMJ (2016)

If a GP suspects a child has diabetes they should send them to be seen by a multidisciplinary paediatric diabetes team on the same day, the National Institute for Health and Care Excellence (NICE) has said.1

The NICE quality standard, Diabetes in Children and Young People , states that a delay in diagnosis and care puts patients at higher risk of diabetic ketoacidosis, which is life threatening but preventable.

Diabetes is becoming more common in the UK; around 26 400 children have type 1 diabetes and 500 have type 2 diabetes.

The quality standard said that, at diagnosis, children with type 1 diabetes should …
포스터 전시 : 원발성 담즙성 간경변증 환자들의 초기 임상 양상
Authors: 염문선, 유권, 이한효, 김성은, 심기남, 정성애, 문일환
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 원발성 담즙성 간경변증은 자가면역성 간질환으로 중년 여성에서 호발한다. 검사실 소견상 담즙정체성 간기능 이상과 항미토콘드리아항체 양성을 특징으로 하며 조직검사상 림프구 위주의 간문맥 주변부 염증과 섬유화가 관찰된다. Ursodeoxycholic acid (UDCA)가 임상적 호전을 나타내는 약물로 알려져 있다. 저자들은 간기능검사의 이상으로 본원에 내원한 환자에 대한 진단과정에서 원발성 담즙성 간경변증으로 처음 진단된 9명의 환자들에 대한 초기 임상양상에 대해 알아 보고자 하였다. 대상과 방법 : 2001년 1월부터 2003년 4월사이에 본원에 내원하여 원발성 담즙성 간경변증으로 진단된 9명을 대상으로 진단 당시의 초기 소견을 조사하였으며, 이 환자중 6개월 이상 UDCA를 투여한 7명의 환자에서 간기능 검사를 추적관찰 하였다. 결과: 평균 연령은 55.7(36-73)세 였으며, 남녀 비는 3:6으로 여성이 많았다. 내원동기는 우연히 발견된 간기능 이상이 6명(67%), 만성피로감 2명(22%), 소양증 1명(11%)이었다. 모든 환자에서 항미토콘드리아항체가 양성이었으며 다른 종류의 만성 간질환은 배제되었다. 영상학적 검사상 2명의 환자에서 간경변증의 소견을 보였다. 내원시의 간기능 검사는(평균치) AST 106 IU/L, ALT 114 IU/L, ALP 1005 IU/L, rGTP 476 IU/L, 총빌리루빈 1.22 mg/dL로 증가된 소견보였으며, 총콜레스테롤은 220 mg/dL으로 정상소견을 보였다. 처음 진단받은후 6개월이상 UDCA (15mg/kg/day)를 투여한 7명의 환자에서 6개월 치료후 간기능 검사에서는 AST 37 IU/L(P=0.03), ALT 30 IU/L(P=0.06), ALP 393 IU/L(P=0.02), rGTP 117 IU/L(P=0.02), 총빌리루빈 1.20 mg/dL(P=0.7)로 호전된 소견을 보였다. 결론: 원발성 담즙성 간경변증 환자는 처음 진단시의 생화학적 검사상 담즙정체성 간기능 이상을 뚜렷이 보였으며 UDCA 치료로 현저한 호전을 나타냄을 알수 있었고 향후 UDCA의 치료효과에 대한 장기적 추적 관찰이 요망된다.
Mitochondrial heteroplasmy in vertebrates using ChIP-sequencing data
Authors: Thomas Rensch, Diego Villar, Julie Horvath, Duncan T. Odom, Paul Flicek
Journal: Genome biology (2016)

Mitochondrial heteroplasmy, the presence of more than one mitochondrial DNA (mtDNA) variant in a cell or individual, is not as uncommon as previously thought. It is mostly due to the high mutation rate of the mtDNA and limited repair mechanisms present in the mitochondrion. Motivated by mitochondrial diseases, much focus has been placed into studying this phenomenon in human samples and in medical contexts. To place these results in an evolutionary context and to explore general principles of heteroplasmy, we describe an integrated cross-species evaluation of heteroplasmy in mammals that exploits previously reported NGS data. Focusing on ChIP-seq experiments, we developed a novel approach to detect heteroplasmy from the concomitant mitochondrial DNA fraction sequenced in these experiments. We first demonstrate that the sequencing coverage of mtDNA in ChIP-seq experiments is sufficient for heteroplasmy detection. We then describe a novel detection method for accurate detection of heteroplasmies, which also accounts for the error rate of NGS technology. Applying this method to 79 individuals from 16 species resulted in 107 heteroplasmic positions present in a total of 45 individuals. Further analysis revealed that the majority of detected heteroplasmies occur in intergenic regions. In addition to documenting the prevalence of mtDNA in ChIP-seq data, the results of our mitochondrial heteroplasmy detection method suggest that mitochondrial heteroplasmies identified across vertebrates share similar characteristics as found for human heteroplasmies. Although largely consistent with previous studies in individual vertebrates, our integrated cross-species analysis provides valuable insights into the evolutionary dynamics of mitochondrial heteroplasmy.
The genetics of nodal marginal zone lymphoma
Authors: Valeria Spina, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano Cascione, Alessio Bruscaggin, Elisa Spaccarotella, Antony B. Holmes, Luca Arcaini, Marco Lucioni, Fabrizio Tabbò, Sakellarios Zairis, Fary Diop, Michaela Cerri, Sabina Chiaretti, Roberto Marasca, Maurilio Ponzoni, Silvia Deaglio, Antonio Ramponi, Enrico Tiacci, Laura Pasqualucci, Marco Paulli, Brunangelo Falini, Giorgio Inghirami, Francesco Bertoni, Robin Foà, Raul Rabadan, Gianluca Gaidano, Davide Rossi
Journal: Blood (2016)
An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.
Authors: Y. Ung, C. Gu, K. Cline, A. Sun, R. M. MacRae, J. R. Wright, E. Yu, L. Ehrlich, K. Y. Gulenchyn, H. Shulman, I. S. Dayes, S. K. Dhesy-Thind, G. E. Darling, N. B. Leighl, W. K. Evans, J. A. Julian, M. N. Levine
Journal: Journal of Clinical Oncology (2011)

7018 Background: Patients with stage 3 NSCLC are potentially curable using combined modality therapy (CMT) with chemotherapy and radical radiation therapy (RT). PET/CT imaging is commonly used to stage patients with NSCLC. In addition, PET/CT for planning of RT may improve the definition of RT treatment volumes compared with conventional CT planning and thus improve outcomes. Methods: Patients with stage 3 NSCLC, who were considered candidates for CMT, were randomized to either PET/CT or CT alone for RT treatment planning. The proportion of patients who did not receive CMT because their tumor was upstaged to stage 4 or their intra-thoracic tumor was too extensive for radical RT was presented at the ASCO 2009 meeting. The secondary outcomes of overall survival (OS) and relationship of the standard uptake value (SUV) and OS are reported now. Results: Overall 310 patients were randomized, 152 to the PET/CT and 158 to standard CT planning. 118 (78%) of the 152 patients randomized to the PET/CT arm received radical RT compared with 146 (92%) of the 158 CT patients. The median follow-up was 17 months. The 2-year OS of the PET/CT group was 47% compared with 39% for the CT arm (hazard ratio [HR] = 0.8; 95% confidence interval [CI]: 0.6 - 1.0). A multivariable analysis (MVA) for OS indicated that in addition to the intervention, stage (3B vs 3A; HR = 1.4, 95% CI: 1.1 - 1.9) and ECOG status (HR = 1.7 per unit increase, 95% CI: 1.3 - 2.6) were predictive of OS. In the 142 PET/CT patients with complete PET scans, a MVA showed that SUV (HR = 1.03 per unit increase, 95% CI: 1.01 - 1.05) and stage (3B vs 3A; HR = 1.9, 95% CI: 1.2 - 3.0) were strong predictors of OS. Conclusions: The PET START trial is the first randomized trial comparing PET/CT planning with standard CT planning in patients with NSCLC. As expected, the use of PET/CT resulted in fewer patients receiving radical RT. The OS trend favoring PET/CT may be primarily due to more accurate staging. The SUV and stage were strong predictors of OS in patients with stage 3 NSCLC.
Abstract 531: lncRNA profiling and its potential usage as thyroid cancer biomarker
Authors: Song Tian, Samuel Rulli, Thomas J. Fahey, Eric Lader
Journal: Cancer Research (2015)

Abstract Thyroid nodules are detected in as high as 67% of the population. Distinguishing thyroid cancers from benign lesions is crucial for determining appropriate and timely treatment. Fast and accurate detection using a simple screening method could greatly contribute to minimizing unnecessary surgery while increasing the accuracy of cancer detection. Several long non-coding RNAs (lncRNAs) have been linked to cancer development as either oncogenes or tumor suppressors, and their potential use as cancer biomarkers has been suggested. Unfortunately, limited analyses have been performed on the expression of lncRNA in thyroid cancer. Here, we explored the possible use of lncRNA as a specific thyroid cancer biomarker. The expression of 84 human cancer-related lncRNAs were evaluated in RNA samples from 9 thyroid cancer (PTC and FVPTC) patients and 13 non-cancer controls (NH and FA) with a simple real-time RT-PCR strategy. PTCSC1, an lncRNA previously linked to thyroid cancer, was found to be down regulated in patient 3.4 fold (p&amp;lt;0.005). In addition, we observed dysregulation of other lncRNA such as BANCR (down 3 fold, p&amp;lt;0.005) and SNHG16 (down 2 fold, p&amp;lt;0.005). We next used the lncRNA expression data for signature panel development to classify benign and malignant thyroid patient tissue samples. With a random forest classification model, a fine tuned classification signature of 16 target genes was reasonably successful (Accuracy 95%, sensitivity 92%, PPV = 90% and NPV = 100%). Our results suggested that in addition to the role that lncRNA plays in thyroid cancer, analysis of lncRNA expression represents a promising path towards a simple test for thyroid cancer detection. Citation Format: Song Tian, Samuel Rulli, Thomas J. Fahey, Eric Lader. lncRNA profiling and its potential usage as thyroid cancer biomarker. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 531. doi:10.1158/1538-7445.AM2015-531